MET and neoplasm: These resistance mechanisms include secondary mutations in oncogenes (such as EGFR T790M and C797S), activation of bypass signaling pathways (e.g., MET amplification), phenotypic transitions, such as the epithelial-to-mesenchymal shift, and the development of an immunosuppressive tumor microenvironment [156].